STLN
Income statement / Annual
Last year (2025), Starling Oncolog's total revenue was $502.73 M,
and the percentage change from the previous year is not available.
In 2025, Starling Oncolog's net income was -$60.61 M.
See Starling Oncolog,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
| Period Ended |
12/31/2025 |
| Operating Revenue |
$502.73 M |
| Cost of Revenue |
$426.29 M
|
| Gross Profit |
$76.44 M
|
| Gross Profit Ratio |
0.15
|
| Research and Development Expenses |
$0.00
|
| General & Administrative Expenses |
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
| Selling, General & Administrative Expenses |
$105.57 M
|
| Other Expenses |
$6.94 M
|
| Operating Expenses |
$112.52 M
|
| Cost And Expenses |
$538.81 M
|
| Interest Income |
$0.00
|
| Interest Expense |
$11.28 M
|
| Depreciation & Amortization |
$6.94 M
|
| EBITDA |
-$42.52 M |
| EBITDA Ratio |
-0.08
|
| Operating Income Ratio |
-0.07
|
| Total Other Income/Expenses Net |
-$24.65 M
|
| Income Before Tax |
-$60.74 M
|
| Income Before Tax Ratio |
-0.12
|
| Income Tax Expense |
-$131.00 K
|
| Net Income |
-$60.61 M
|
| Net Income Ratio |
-0.12
|
| EPS |
-0.54 |
| EPS Diluted |
-0.54 |
| Weighted Average Shares Out |
$92.39 M
|
| Weighted Average Shares Out Diluted |
$92.39 M
|
| Link |
|
